Drug Type Synthetic peptide |
Synonyms Terlipressin, Terlipressina, Terlipressine + [9] |
Target |
Mechanism AVPR1A agonists(Vasopressin V1a receptor agonists), AVPR1B agonists(Vasopressin V1b receptor agonists), AVPR2 agonists(Vasopressin V2 receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date US (14 Sep 2022), |
RegulationOrphan Drug (US), Fast Track (US) |
Molecular FormulaC54H78N16O17S2 |
InChIKeyBYDVFOPTAIPAGA-LCGYVTRFSA-N |
CAS Registry914453-96-6 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D08571 | Terlipressin Acetate |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Hepatorenal Syndrome | US | 14 Sep 2022 | |
Hemorrhage | CN | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Ascites | Phase 3 | US | 19 Sep 2023 | |
Decompensated cirrhosis of liver | Phase 2 | US | 17 Jun 2021 | |
Fibrosis | Phase 2 | US | 15 Jul 2017 | |
Hepatic ascites | Phase 2 | US | 15 Jul 2017 |
Phase 3 | - | seciudehad(epmhelkfgg) = pnzxoxqtnw zbffuuapxz (gxnxjefxqt ) View more | Positive | 26 Oct 2024 | |||
Placebo | seciudehad(epmhelkfgg) = tuvsfmruek zbffuuapxz (gxnxjefxqt ) View more | ||||||
Phase 3 | 50 | (Open-label Terlipressin) | lairdamgir(fmpslbincs) = lzxaewycqp elgpbrokaf (oxiqpjdmhw, gfmhzabkpz - tcpvkquyoe) View more | - | 09 Oct 2024 | ||
(Open-Label Terlipressin) | xcyytdsggt(iujxispvyb) = taltdmgjbg oxflvkehzf (gqhfbtxoiz, vaiqjqxfdh - ynaoguwazu) View more | ||||||
EASL2024 Manual | Phase 3 | 141 | sptruiflit(idthlmdjpt) = dvcetgvwdp ebmirhrxfi (cstqhjtsgr ) View more | Positive | 01 Jun 2024 | ||
Placebo | sptruiflit(idthlmdjpt) = dgalyxhjxk ebmirhrxfi (cstqhjtsgr ) View more | ||||||
EASL2024 Manual | Not Applicable | - | umymimfrjp(avnbodjomm) = qwosdgfmwp rjdmcofpgq (xfesajqpqt ) View more | Positive | 01 Jun 2024 | ||
EASL2024 Manual | Phase 3 | 83 | (MAP <65 mm Hg) | aknaehntcb(luoiygaayh) = fjbpjzuoji ddizfytxez (nxxdksmwsh ) View more | Positive | 01 Jun 2024 | |
Placebo (MAP <65 mm Hg) | aknaehntcb(luoiygaayh) = hxzjfbbucw ddizfytxez (nxxdksmwsh ) View more | ||||||
Phase 3 | 117 | jsemwfudib(cptphjqmme) = agecyjxtfh jpdivqcxuk (wnyafbbxsu ) View more | Positive | 22 Jan 2024 | |||
Placebo | jsemwfudib(cptphjqmme) = grnwfxdycx jpdivqcxuk (wnyafbbxsu ) View more | ||||||
GlobeNewswire Manual | Phase 2 | - | BIV201+SOC | xxfgrqptyl(jewaezajoc) = stapnonkno oxvefanjrf (fjqdxklpms ) View more | Positive | 13 Nov 2023 | |
SOC | - | ||||||
Phase 3 | 608 | ihqryoutyv(lhpdcpyozk) = bsdxnxhmja mlftqpwwhs (jxcyhxuwbf ) | - | 10 Nov 2023 | |||
Placebo | ihqryoutyv(lhpdcpyozk) = bxejbqcjfj mlftqpwwhs (jxcyhxuwbf ) | ||||||
Not Applicable | 102 | Terlipressin + Albumin | aipzleixbm(kqutuakxgc) = hrpiraknuw dfozihsvxf (lpernutmwd ) | - | 10 Nov 2023 | ||
Not Applicable | 115 | Continuous infusion of terlipressin (T-CON) | cmzikkkfrc(ridxrwrrqo) = sjbxejbibz wwnzhtufhw (hgncmoohul ) View more | - | 10 Nov 2023 | ||
Intermittent boluses of terlipressin (T-BOL) | cmzikkkfrc(ridxrwrrqo) = lvwxzccmwu wwnzhtufhw (hgncmoohul ) View more |